Liver health screening for metabolic disease
Part of Digestive system, Hormones & metabolism clinical trials.
This study screens people with overweight, obesity, or certain metabolic risk factors (like high blood pressure or diabetes) to find early signs of fatty liver disease and other liver problems. The goal is to improve prevention and early treatment through better screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have overweight or obesity (BMI ≥ 25), or an increased waist size, or at least one metabolic risk factor such as high blood pressure, high cholesterol, prediabetes, or type 2 diabetes.
- You must be part of the ENDOCARE screening program.
- You must be able to give written informed consent, including for use of your health data.
- You must not be pregnant or breastfeeding.
- You must not have advanced liver disease, and you must agree to blood tests and liver ultrasound if required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
This study follows up on people with type 2 diabetes who already took part in an earlier study about liver health. It uses an MRI scan to check the liver for fat and other changes, helping doctors understand the long-term impact of metabolic dysfunction-associated steatotic liver disease (MASLD).
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.